E. Ohman J or Asset Management AB Purchases 38,400 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

E. Ohman J or Asset Management AB raised its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 400.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,000 shares of the company’s stock after acquiring an additional 38,400 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Dr. Reddy’s Laboratories were worth $758,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its position in Dr. Reddy’s Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Artemis Investment Management LLP boosted its position in Dr. Reddy’s Laboratories by 398.3% during the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock valued at $4,666,000 after acquiring an additional 236,224 shares during the last quarter. Fisher Asset Management LLC boosted its position in Dr. Reddy’s Laboratories by 59.4% during the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after acquiring an additional 183,146 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Dr. Reddy’s Laboratories by 219.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock valued at $12,353,000 after acquiring an additional 106,796 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in Dr. Reddy’s Laboratories by 441.8% during the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company’s stock valued at $1,992,000 after acquiring an additional 102,226 shares during the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $13.98 on Thursday. The stock has a market capitalization of $11.67 billion, a PE ratio of 22.25 and a beta of 0.50. The company’s 50-day moving average is $14.79 and its 200-day moving average is $15.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. Dr. Reddy’s Laboratories Limited has a 1 year low of $13.36 and a 1 year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Finally, Barclays cut their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.